ARUP's Laboratory Test Directory

Beta-hCG, Quantitative (Tumor Marker), CSF : 0020730

Mnemonic: BHCG CSF

Methodology: Quantitative Electrochemiluminescent Immunoassay
Performed: Sun-Sat
Reported: Within 24 hours
Specimen Required: Collect: CSF. Also acceptable: CSF collected in plain red or green (sodium or lithium heparin).

Specimen Preparation: Transfer 0.5 mL CSF to an ARUP Standard Transport Tube. (Min: 0.3 mL)

Storage/Transport Temperature: Refrigerated.

Unacceptable Conditions: Any other body fluids.

Stability (collection to initiation of testing): Ambient: 8 hours; Refrigerated: 1 week; Frozen: 2 months
Reference Interval:
18 years and older: 0-3 IU/L
Interpretive Data: Human chorionic gonadotropin (hCG) is a valuable aid in the management of patients with trophoblastic tumors, nonseminomatous testicular tumors, and seminomas when used in conjunction with information available from the clinical evaluation and other diagnostic procedures. Increased hCG concentrations have also been observed in melanoma, carcinomas of the breast, gastrointestinal tract, lung, and ovaries, and in benign conditions including cirrhosis, duodenal ulcer, and inflammatory bowel disease. The result cannot be interpreted as absolute evidence of the presence or absence of malignant disease. The result is not interpretable as a tumor marker in pregnant females.

The combination of the specific monoclonal antibodies used in the Roche Beta HCG electrochemiluminescent immunoassay recognize the holo-hormone, "nicked" forms of hCG, the beta-core fragment, and the free beta-subunit. Although this assay is FDA cleared for use in the detection of pregnancy, it is not labeled for use as a tumor marker or with CSF specimens. The performance characteristics of this assay were determined by ARUP.
CPT Code(s): 84702
 
 

 

 

 
All ARUP Sites:        www.aruplab.com     ·     www.arupconsult.com     ·     www.arup.utah.edu     ·     www.childx.org     ·     www.utahblood.org